INCY — Incyte Corporation

Summary of Incyte Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $1.27 billion, up 21% year-over-year.
• Net Sales: $1.1 billion, representing a 20% increase from the previous year.
• Jakafi Sales: $758 million, a 7% year-over-year growth.
• Core Business (excluding Jakafi): Sales increased by 63% year-over-year, totaling $342 million.
• GAAP R&D Expenses: $516 million, an 18% increase year-over-year.
• GAAP SG&A Expenses: $328 million, a modest 1% increase year-over-year.
• Operating Margin Improvement: Operating expenses grew at a slower rate than revenues, indicating improved operational leverage.

2. Strategic Updates and Business Highlights

• Incyte is transitioning from reliance on Jakafi to a diversified portfolio in hematology, oncology, and immunology.
• Key regulatory milestones include the FDA's acceptance of the application for povorcitinib for hidradenitis suppurativa (HS) and positive Phase III results for vitiligo.
• Upcoming product launches include Jakafi XR, Opzelura for atopic dermatitis in Europe, Monjuvi for first-line DLBCL, and povorcitinib for HS.
• Significant executive appointments were made to strengthen management, including Suky Upadhyay as CFO and Pablo Cagnoni as President and Global Head of R&D.

3. Forward Guidance and Outlook

• Full-year 2026 net sales guidance is set between $4.77 billion and $4.94 billion, reflecting a 10% to 13% increase from 2025.
• Jakafi sales are expected to be between $3.22 billion and $3.27 billion, while Opzelura is projected to generate $750 million to $790 million.
• The core business (excluding Jakafi) is anticipated to approach $3 billion to $4 billion by 2030.

4. Bad News, Challenges, or Points of Concern

• The company faces competitive pressures in the dermatological market, particularly with Opzelura, as it competes against other non-steroidal topicals.
• The reliance on Jakafi, despite its growth, poses a risk as Incyte aims to diversify its portfolio.
• The timeline for regulatory approvals, particularly for pivotal studies, could be impacted by ongoing discussions with the FDA regarding endpoints and trial designs.
• There is uncertainty regarding the uptake of povorcitinib in the HS market, particularly in distinguishing its use among biologic-naive patients versus those who have failed biologics.

5. Notable Q&A Insights

• Management expressed optimism about the potential for povorcitinib to capture a significant share of the HS market, targeting both pre- and post-biologic patients.
• The company is confident in the unique positioning of its products, with a focus on a "topical to oral" treatment strategy for vitiligo and HS.
• Discussions with the FDA have been constructive, particularly regarding the development of the mutant CALR antibody 989, which is expected to initiate Phase III trials mid-year.
• Management emphasized the importance of maintaining operational efficiency and strategic capital allocation under the new CFO's leadership.
• There was a strong focus on the potential synergies between Jakafi and the new therapies in the pipeline, particularly for patients with CALR mutations in myelofibrosis.

Overall, Incyte reported a strong start to 2026 with significant revenue growth and strategic advancements, while also navigating competitive pressures and regulatory challenges.